Your AI-Trained Oncology Knowledge Connection!

Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC) : Episode 4

Opinion

Video

March 29, 2024

Predisposition for Patients Developing DTC: Age and Gender

The panel explores potential reasons for the higher incidence of thyroid cancer diagnoses in women compared to men, while also discussing diagnosis in the pediatric population and examining the influence of environmental and genetic factors on detection bias.

EP: 1.Differentiated Thyroid Cancer: Examining Key Epidemiological Trends

EP: 2.Exploring Incidence and Histology of Differentiated Thyroid Cancer

EP: 3.Determining Prognosis for Patients with Differentiated Thyroid Cancer

Now Viewing

EP: 4.Predisposition for Patients Developing DTC: Age and Gender

EP: 5.The Role of Molecular Diagnostics in Real-World DTC Management

EP: 6.Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies

EP: 7.The Importance of Thyroidectomy in DTC Patient Care

EP: 8.Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression

EP: 9.Identifying RAI-Refractory Disease: A Key Aspect of DTC Management

EP: 10.SELECT Trial & DECISION Trial Outcomes and Lessons Learned

EP: 11.Determining Which DTC Patients May Benefit from Systemic Therapy

EP: 12.Exploring Real-World Evidence Presented at ATA 2023

EP: 13.Understanding the Impact of COSMIC-311 and Sequencing in DTC

EP: 14.Toxicity Profiles for DTC Guidelines Therapies

EP: 15.Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment

EP: 16.Neoadjuvant Approach in RAI-R-DTC

EP: 17.Phase 2 ATLEP Trial Results

EP: 18.Reflecting on Differentiated Thyroid Cancer: Final Insights

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

May 8th 2025 - May 9th 2026

online-activity

Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity

Latest Conference Coverage

Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025

Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Ultra-Low PSA Response With Darolutamide/ADT Correlates With Better Outcomes in mHSPC

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Predisposition for Patients Developing DTC: Age and Gender

EP: 1.Differentiated Thyroid Cancer: Examining Key Epidemiological Trends

EP: 2.Exploring Incidence and Histology of Differentiated Thyroid Cancer

EP: 3.Determining Prognosis for Patients with Differentiated Thyroid Cancer

EP: 4.Predisposition for Patients Developing DTC: Age and Gender

EP: 5.The Role of Molecular Diagnostics in Real-World DTC Management

EP: 6.Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies

EP: 7.The Importance of Thyroidectomy in DTC Patient Care

EP: 8.Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression

EP: 9.Identifying RAI-Refractory Disease: A Key Aspect of DTC Management

EP: 10.SELECT Trial & DECISION Trial Outcomes and Lessons Learned

EP: 11.Determining Which DTC Patients May Benefit from Systemic Therapy

EP: 12.Exploring Real-World Evidence Presented at ATA 2023

EP: 13.Understanding the Impact of COSMIC-311 and Sequencing in DTC

EP: 14.Toxicity Profiles for DTC Guidelines Therapies

EP: 15.Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment

EP: 16.Neoadjuvant Approach in RAI-R-DTC

EP: 17.Phase 2 ATLEP Trial Results

EP: 18.Reflecting on Differentiated Thyroid Cancer: Final Insights

Newsletter

Latest CME

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Latest Conference Coverage